BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 24870772)

  • 1. Third-line hormonal therapy to treat prostate cancer relapse after initial and second-line hormonal therapy: report of 52 cases and literature review.
    Matsumoto K; Hagiwara M; Hayakawa N; Tanaka N; Ito Y; Maeda T; Ninomiya A; Nagata H; Nakamura S
    Asian Pac J Cancer Prev; 2014; 15(8):3645-9. PubMed ID: 24870772
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hot flashes during androgen deprivation therapy with luteinizing hormone-releasing hormone agonist combined with steroidal or nonsteroidal antiandrogen for prostate cancer.
    Sakai H; Igawa T; Tsurusaki T; Yura M; Kusaba Y; Hayashi M; Iwasaki S; Hakariya H; Hara T; Kanetake H
    Urology; 2009 Mar; 73(3):635-40. PubMed ID: 19038426
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical efficacy of primary combined androgen blockade for Japanese men with clinically localized prostate cancer unsuitable for local definitive treatment: a single institution experience.
    Kobayashi M; Nukui A; Suzuki K; Kurokawa S; Morita T
    Int J Clin Oncol; 2011 Dec; 16(6):630-6. PubMed ID: 21512893
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of Immediate Switching from Bicalutamide to Flutamide as Second-Line Combined Androgen Blockade.
    Yokomizo Y; Kawahara T; Miyoshi Y; Otani M; Yamanaka S; Teranishi J; Noguchi K; Yao M; Uemura H
    Biomed Res Int; 2016; 2016():4083183. PubMed ID: 27493956
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alternative nonsteroidal antiandrogen therapy for advanced prostate cancer that relapsed after initial maximum androgen blockade.
    Suzuki H; Okihara K; Miyake H; Fujisawa M; Miyoshi S; Matsumoto T; Fujii M; Takihana Y; Usui T; Matsuda T; Ozono S; Kumon H; Ichikawa T; Miki T;
    J Urol; 2008 Sep; 180(3):921-7. PubMed ID: 18635218
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alternative antiandrogens to treat prostate cancer relapse after initial hormone therapy.
    Kojima S; Suzuki H; Akakura K; Shimbo M; Ichikawa T; Ito H
    J Urol; 2004 Feb; 171(2 Pt 1):679-83. PubMed ID: 14713785
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prostate-specific antigen response to deferred combined androgen blockade therapy using bicalutamide predicts survival after subsequent oestrogen and docetaxel therapies in patients with castration-resistant prostate cancer.
    Kijima T; Fujii Y; Yokoyama M; Ishioka J; Matsuoka Y; Numao N; Saito K; Koga F; Masuda H; Kawakami S; Kihara K
    BJU Int; 2012 Oct; 110(8):1149-55. PubMed ID: 22369348
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bicalutamide 150 mg as secondary hormonal therapy for castration-resistant prostate cancer.
    Qian SB; Shen HB; Cao QF; Zhang L; Chen YF; Qi J
    Int Urol Nephrol; 2015 Mar; 47(3):479-84. PubMed ID: 25665794
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of goserelin and leuprolide in combined androgen blockade therapy.
    Sarosdy MF; Schellhammer PF; Sharifi R; Block NL; Soloway MS; Venner PM; Patterson AL; Vogelzang NJ; Chodak GW; Klein EA; Schellenger JJ; Kolvenbag GJ
    Urology; 1998 Jul; 52(1):82-8. PubMed ID: 9671875
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Deferred combined androgen blockade therapy using bicalutamide in patients with hormone-refractory prostate cancer during androgen deprivation monotherapy.
    Fujii Y; Kawakami S; Masuda H; Kobayashi T; Hyochi N; Kageyama Y; Kihara K
    BJU Int; 2006 Jun; 97(6):1184-9. PubMed ID: 16686709
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alternative antiandrogen therapy in patients with castration-resistant prostate cancer: a single-center experience.
    Okegawa T; Nutahara K; Higashihara E
    Int J Urol; 2010 Nov; 17(11):950-5. PubMed ID: 20807265
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Failure to achieve castrate level of serum testosterone during luteinizing hormone-releasing hormone agonist therapy in a patient with prostate cancer.
    Koh Y; Kawashima A; Ujike T; Nagahara A; Fujita K; Kiuchi H; Imamura R; Miyagawa Y; Nonomura N; Uemura M
    Anticancer Drugs; 2020 Nov; 31(10):1099-1102. PubMed ID: 32804697
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enzalutamide versus flutamide for castration-resistant prostate cancer after combined androgen blockade therapy with bicalutamide: the OCUU-CRPC study.
    Iguchi T; Tamada S; Kato M; Yasuda S; Machida Y; Ohmachi T; Ishii K; Iwata H; Yamamoto S; Kanamaru T; Morimoto K; Hase T; Tashiro K; Harimoto K; Deguchi T; Adachi T; Iwamoto K; Takegaki Y; Nakatani T
    Int J Clin Oncol; 2020 Mar; 25(3):486-494. PubMed ID: 31564004
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of localized prostate cancer with intermittent triple androgen blockade: preliminary results in 110 consecutive patients.
    Leibowitz RL; Tucker SJ
    Oncologist; 2001; 6(2):177-82. PubMed ID: 11306729
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Determination of enzalutamide long-term safety and efficacy for castration-resistant prostate cancer patients after combined anti-androgen blockade followed by alternative anti-androgen therapy: a multicenter prospective DELC study.
    Nagahara A; Uemura M; Sato M; Nakata W; Tsujihata M; Takao T; Matsumura S; Nishimura K; Takada S; Iwanishi T; Kobayashi Y; Ishizuya Y; Takada T; Okada K; Inoue H; Kato T; Hatano K; Kawashima A; Ujike T; Fujita K; Nonomura N
    Jpn J Clin Oncol; 2024 May; 54(5):584-591. PubMed ID: 38305451
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Undetectable level of prostate specific antigen (PSA) nadir predicts PSA biochemical failure in local prostate cancer with delayed-combined androgen blockade.
    Soga N; Arima K; Sugimura Y
    Jpn J Clin Oncol; 2008 Sep; 38(9):617-22. PubMed ID: 18697759
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An open-label, phase 2 trial of bicalutamide dose escalation from 50 mg to 150 mg in men with CAB and castration resistance. A Canadian Urology Research Consortium Study.
    Klotz L; Drachenberg D; Singal R; Aprikian A; Fradet Y; Kebabdjian M; Zarenda M; Chin J
    Prostate Cancer Prostatic Dis; 2014 Dec; 17(4):320-4. PubMed ID: 25179591
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prior switching to a second-line nonsteroidal antiandrogen does not impact the therapeutic efficacy of abiraterone acetate in patients with metastatic castration-resistant prostate cancer: a real-world retrospective study.
    Zhao JG; Liu JD; Shen PF; Tang X; Sun GX; Zhang XM; Chen JR; Shu KP; Shi M; Zeng H
    Asian J Androl; 2018; 20(6):545-550. PubMed ID: 30106011
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Does prolonged combined androgen blockade have survival benefits over short-term combined androgen blockade therapy?
    Sarosdy MF; Schellhammer PF; Johnson R; Carroll K; Kolvenbag GJ
    Urology; 2000 Mar; 55(3):391-5; discussion 395-6. PubMed ID: 10699617
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical efficacy of alternative antiandrogen therapy in Japanese men with relapsed prostate cancer after first-line hormonal therapy.
    Okihara K; Ukimura O; Kanemitsu N; Mizutani Y; Kawauchi A; Miki T;
    Int J Urol; 2007 Feb; 14(2):128-32. PubMed ID: 17302569
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.